‒ The Fund has now committed a total of USD 48 million to eight companies
‒ REPAIR to adjust strategic scope for 2020
‒ Global call for investment proposals will open during summer of 2020
Today, the Novo Holdings REPAIR Impact Fund announced a EUR 7 [USD 8] million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France. This investment will allow the company to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.
“We look forward to working with the team at Novo Holdings REPAIR Impact Fund. REPAIR’s commitment to funding the development of novel antibiotics will provide us with the essential support we need to accelerate our lead asset to where it is most needed – the clinic as we strive to bring new antibiotics to the market to combat the growing threat of drug-resistant bacteria.” said Stéphane Huguet Mutabilis’s Chief Executive Officer.
Full PR available here